ReviewFrontiers in medicine2018
Endothelial Progenitor Cells: New Targets for Therapeutics for Inflammatory Conditions With High Cardiovascular Risk.
Review in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- Sucralose inhibited cell survival through the activation of ER stress in human endothelial progenitor cells.PloS one · 2026Article
- Endothelial Progenitor Cells in Life, Pregnancy and Disease.Expert reviews in molecular medicine · 2025Review
- Review
- Isolation and Characterization of Endothelial-Colony Forming Cells (ECFC): Studying Endothelial Senescence for Translational Studies and for Personalized Medicine.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Role of Peripheral Blood Regulatory T Cells and IL-2 in the Collateral Circulation of Acute Ischemic Stroke.International journal of general medicine · 2025Article
- Unravelling the Mechanisms of Oxidised Low-Density Lipoprotein in Cardiovascular Health: Current Evidence from In Vitro and In Vivo Studies.International journal of molecular sciences · 2024Review
- Endothelial Progenitor Cells: A Brief Update.International journal of stem cells · 2024Review
- The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia.International journal of molecular sciences · 2024Review
- Markers of Endothelial Dysfunction in Kawasaki Disease: An Update.Clinical reviews in allergy & immunology · 2024Review
- Endothelial Progenitor Cell (EPC) is a Prime Target in Diabetic Wound Healing: Mechanisms and Target Therapies.Current molecular medicine · 2024Article
- Circulating endothelial progenitor cell dysfunction in patients with bipolar disorder.European archives of psychiatry and clinical neuroscience · 2023Article
- Novel Function of Nogo-A as Negative Regulator of Endothelial Progenitor Cell Angiogenic Activity: Impact in Oxygen-Induced Retinopathy.International journal of molecular sciences · 2023Article
- Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings.International journal of molecular sciences · 2023Review
- A tryptophan metabolite prevents depletion of circulating endothelial progenitor cells in systemic low-grade inflammation.Frontiers in immunology · 2023Article
- The myeloid mineralocorticoid receptor regulates dermal angiogenesis and inflammation in glucocorticoid-induced impaired wound healing.British journal of pharmacology · 2022Article
- Functional Impairment of Endothelial Colony Forming Cells (ECFC) in Patients with Severe Atherosclerotic Cardiovascular Disease (ASCVD).International journal of molecular sciences · 2022Article
- Resident vascular endothelial progenitor definition and function: the age of reckoning.Angiogenesis · 2022Review
- Endothelial Progenitor Cells and Rheumatoid Arthritis: Response to Endothelial Dysfunction and Clinical Evidences.International journal of molecular sciences · 2021Review
- Endothelial Progenitor Cells Dysfunctions and Cardiometabolic Disorders: From Mechanisms to Therapeutic Approaches.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decade, we have witnessed an exponential growth of interest into the role of endothelial progenitor cells (EPCs) in cardiovascular disease. While the major thinking revolves around EPC angiogenic repair properties, we have used a hypothesis-driven approach to discover disease-related defects in their characteristics and based on these findings, have identified opportunities for functional enhancement, which offer an exciting avenue for translation into clinical intervention. In this review, we focus on two groups; circulating myeloid angiogenic cells (MACs) and late outgrowth endothelial colony forming cells (ECFCs), and will discuss the unique properties and defects of each population, as new insights have been gained into the potential function of each sub-type using current techniques and multiomic technology. We will discuss their role in inflammatory disorders and alterations in mitochondrial function. In addition, we share key insights into the glycocalyx, and propose this network of membrane-bound proteoglycans and glycoproteins, covering the endothelium warrants further investigation in order to clarify its significance in ECFC regulation of vascularization and angiogenesis and ultimately for potential translational therapeutic aspects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.